Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Shares, no par value per share
-
Shares outstanding
-
5.78M
-
Number of holders
-
6
-
Total 13F shares, excl. options
-
287K
-
Shares change
-
+262K
-
Total reported value, excl. options
-
$325K
-
Value change
-
+$296K
-
Number of buys
-
2
-
Number of sells
-
-4
-
Price
-
$1.13
Significant Holders of XORTX Therapeutics Inc. - Common Shares, no par value per share (XRTX) as of Q4 2024
8 filings reported holding XRTX - XORTX Therapeutics Inc. - Common Shares, no par value per share as of Q4 2024.
XORTX Therapeutics Inc. - Common Shares, no par value per share (XRTX) has 6 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 287K shares
of 5.78M outstanding shares and own 4.96% of the company stock.
Largest 8 shareholders include ARMISTICE CAPITAL, LLC (265K shares), UBS Group AG (17.4K shares), NATIONAL BANK OF CANADA /FI/ (1.61K shares), Royal Bank of Canada (1.49K shares), OSAIC HOLDINGS, INC. (1.15K shares), Clearstead Advisors, LLC (277 shares), Tower Research Capital LLC (TRC) (0 shares), and JPMORGAN CHASE & CO (0 shares).
This table shows the top 6 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.